As of Monday, more than 92 million Covid-19 vaccine doses have been administered in the United States, according to the latest data from the Centers for Disease Control and Prevention.
Three vaccines are currently approved by the CDC and the Food and Drug Administration for emergency use, manufactured by Pfizer and Bioentech, Moderna and Johnson & Johnson.
Ticker | Security | The last | Change | Change% |
---|---|---|---|---|
P.F.E. | PFIZER INC. | 34.32 | -0.05 | -0.15% |
BNTX | BIONTECH SE | 90.29 | -5.91 | -6.14% |
MRNA | Modern, Inc. | 123.47 | -8.72 | -6.60% |
J.N.J. | Johnson and Johnson | 157.47 | +1.35 | + 0.86% |
Here is a Fox business roundup of what each company is expected to bring to the vaccine:
End Democrats’ confidence by numbers
Pfizer and Bioentech
The Pfizer and Bioentech vaccine, the first to be approved for emergency use by the FDA in December after being found to be 95% effective, is more than .8 million..8 million of the total vaccine doses currently administered in the United States. CDC.
Pfizer’s latest earnings report notes that comminct profits are 50-50 divided by bioentech. Companies expect the vaccine to generate about 15 15 billion in revenue by 2021. Pfizer and Bioentech plan to supply 1.3 billion doses of the vaccine worldwide by the end of 2021. The vaccine, which requires two doses, costs $ 39 in the United States. States in the European Union and 28.
Following Komernati’s approval, the United States agreed to pay the companies પ્રથમ 1.95 billion on the first acquisition of 100 million doses. The agreement also allowed the federal government to purchase an additional 50 million doses. That month, Pfizer, Bioentech and the federal government reached a second agreement for the same 100 1.95 billion tag for 100 million more doses. Under the second agreement, the companies will deliver at least 70 million doses by June 30, with the remaining 30 million doses delivered no later than July 31. The government also has the option to acquire up to an additional Rs 400 million. Dosage.
Pfizer and Bioentech also announced in November an agreement with the European Commission for 200 million doses of the vaccine to be distributed in the 27 member states of the European Union, with the option to request an additional 100 million doses. The European Commission made that request in December, Pfizer said.
Last month, Fitzgerald said it had reached a second agreement with the European Commission for an additional 200 million doses, of which 75 million would be provided in the second quarter of 2021. The total number of doses to be delivered to EU member states is now expected to reach 500 million by 2021, depending on the options provided in the new agreement.
Employees paying Marriott to get the Coride-19 vaccine
Modern
According to the CDC, the Modern MRNA-1273 vaccine is approved for emergency use by the FDA after being found to be .5 ..% effective, which, according to the CDC, amounts to .944..9 million of the total vaccine doses administered in the United States. Is higher.
The company said in its fourth-quarter earnings report that it expects expected product sales of .4 18.4 billion related to the state-of-the-art purchase agreement for its vaccine. Modern is on track to place the first 100 million doses in the first quarter of 2021 and the second 100 million doses in May 2021. The company aims to supply up to 1 billion doses in 2021 and 1.4 billion doses in 2022. .
With the option to purchase an additional 200 million doses, Moderna has signed an agreement with the United States for 300 million doses. In addition, the company has agreements with the European Union (310 million doses with the option to purchase an additional 150 million doses in 2022), Japan (50 million doses), Canada (44 million doses), and the Republic of Korea (40 million doses). ), United Kingdom (17 million doses), Switzerland (13.5 million doses), Colombia (10 million doses), Israel (6 million doses) and Taiwan (5 million doses).
Moderna Takes જરૂરી 30 for two shots required in and 36 36 in the EU
Get Fox Business on the go by clicking here
The Johnson & Johnson vaccine, manufactured by its pharmaceutical subsidiary Janssen, was approved for emergency use by the FDA on February 27, and an official ticket of approval was issued by the CDC a day later.
According to the analysis by the FDA, the Johnson vaccine was about 67% effective in preventing moderate to severe cases 14 days after dosing and 66% effective in severe cases after 28 days. In addition, the vaccine was about 77% effective in preventing severe or complex COVID-19 occurring at least 14 days after vaccination and 85% effective in preventing severe or complex COVID-19 occurring at least 28 days after vaccination.
The company is currently working to deliver 3.9 million doses of its initial supply to state health departments, pharmacies, federally qualified health centers and community vaccination centers. Johnson and Johnson are expected to vaccinate more than 20 million Americans by the end of March and 100 million single-shot vaccines by June. Unlike the other two available vaccines, the Jansen vaccine requires one dose.
The company will produce 1 billion doses for global distribution by the end of 2021, which will produce 10 billion. In August, Johnson and Johnson struck a થી 1 billion deal with the U.S. for 100 million doses of its vaccine, with the option to purchase an additional 200 million doses for 10 dollars per shot. In addition, Johnson and Johnson signed an agreement with the EU for 400 million doses.
Click here to read more on Fox Business
According to Johns Hopkins University, the United States has surpassed 29 million COVID-19 cases since the epidemic began in March 2020, with more than 525,000 related deaths.